Overview

Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
To determine if the timing of administration of indomethacin affects the primary outcome of post-ERCP pancreatitis (PEP). Patients undergoing ERCP will be randomly assigned to receive pre or post-procedure rectal indomethacin to prevent the occurrence of PEP.
Phase:
Phase 4
Details
Lead Sponsor:
University of Alberta
Treatments:
Indomethacin